Dr. David Fajgenbaum, Perelman School of Medicine, University of Pennsylvania, says that this is a 47-year-old female who presents with a 10-month history of systemic symptoms comprising night sweats, fatigue, and weight loss accompanied by laboratory values pointing to an inflammatory syndrome or malignancy. [Because] she has generalized lymphadenopathy, the differential diagnosis includes lymphoma, chronic infection, or a systemic inflammatory syndrome [such] as seen in autoimmune disorders. The negative antinuclear antibody (ANA) and other rheumatologic serologies make an autoimmune disorder unlikely. The standardized uptake value (SUV) in the lymph nodes on the positron emission tomography (PET) scan is not very high, but does not rule out lymphoma. The lymph node fine needle aspiration (FNA) was not informative, and the patient was correctly referred for excisional lymph node biopsy.
What does the patient’s initial presentation suggest to you?
Guess the Diagnosis: Case 1
Lisa B. is a 47-year-old female store owner from St. Louis, with a 10-month history of fatigue, night sweats, and weight loss.
Lisa’s pathology report shows the following findings:
In view of these findings, the hematologist orders further tests, which yield the following results:
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Later-Line CD19 and Bispecific Therapies Considered After CAR T
October 1st 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.
Read More
Participants Discuss LOTIS-2 Data Based on Patient Case of DLBCL
September 16th 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed the data behind loncastuximab and whether participants with use this treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma
September 11th 2024The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.
Read More